Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies

University Hospital, Lille

Status: Completed

Conditions: Lactose Intolerance

Treatments: Drug: GED

Study type: Interventional

Funder types: Other

Identifiers

NCT02902016

2013_68

2015-A00259-40 (Other Identifier)

Details and patient eligibility

About

This study is designed to assess the effect of a new PPARgamma modulator on the expression and activity of the lactase enzyme in human intestinal epithelial cells. Based on their previous experimental results, the investigators hypothesized that modulating intestinal PPARgamma activity is a new pharmacological mechanism allowing the control of lactase expression and activity in the gut

Enrollment: 22 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects undergoing gastroduodenal endoscopy for digestive cancer screening
• Subjects undergoing gastroduodenal endoscopy for ulcerative gastroduodenal diseases
• Subjects undergoing gastroduodenal endoscopy for epigastric pains
• Subjects undergoing gastroduodenal endoscopy for gastroesophageal reflux diseases

Exclusion criteria

• Subjects with macroscopic duodenal lesions detected at endoscopy
• Subjects suffering from coeliac disease
• Subjects suffering from atrophic gastritis
• Subjects who use anticoagulant
• Pregnancy or breast feeding

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 1 patient group

Lactase expression induction by GED

Experimental group

Treatment:

Drug: GED